D2 dopaminergic receptors: normal and abnormal transduction mechanisms
- PMID: 1306522
- DOI: 10.1159/000182494
D2 dopaminergic receptors: normal and abnormal transduction mechanisms
Abstract
Dopamine receptors of D2 type present on lactotroph cells are coupled to a large series of transduction mechanisms. Beside their negative coupling with adenylate cyclase, they are also coupled with potassium and calcium channels, leading to a decreased intracellular calcium concentration. In addition, D2 dopamine receptors also modulate phospholipase activities. Dopamine inhibits inositol phosphate production, through two distinct mechanisms. One of them could represent a direct negative coupling with phospholipase C. All these transduction mechanisms of the D2 dopamine receptors implicate G proteins sensitive to pertussis toxin. In contrast, these receptors are negatively coupled to phospholipase A2 through G proteins insensitive to this toxin. Both isoforms of the D2 dopamine receptor, generated by alternate splicing of a single gene, are present in lactotroph cells. After transfection in CH4C1 cells the two isoforms are coupled with adenylate cyclase while only the shortest isoform appears negatively coupled to phospholipase C. Functional D2 dopamine receptors are present in human prolactinomas. Resistance to bromocriptine therapy is associated with a decreased density of these receptors in the tumor. In addition, the ratio of the two receptor isoforms (measured by PCR) is different in responsive and resistant tumors. Furthermore, the activity of Gi/Go proteins coupled to adenylate cyclase appears also affected in resistant tumors. Resistance to bromocriptine therapy appears thus to involve multiple changes at the different levels of the multiple mechanisms of action of dopamine on lactotroph cells.
Similar articles
-
[Membrane receptors and coupling proteins in adenohypophyseal cells].C R Seances Soc Biol Fil. 1993;187(1):14-23. C R Seances Soc Biol Fil. 1993. PMID: 8242419 Review. French.
-
Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.Neuroendocrinology. 1994 Sep;60(3):314-22. doi: 10.1159/000126764. Neuroendocrinology. 1994. PMID: 7969790
-
Resistance to bromocriptine in prolactinomas.J Clin Endocrinol Metab. 1989 Sep;69(3):500-9. doi: 10.1210/jcem-69-3-500. J Clin Endocrinol Metab. 1989. PMID: 2760167
-
Absence of D2S dopamine receptor in the prolactin-secreting MMQ pituitary clone: characterization of a wild D2L receptor coupled to native transduction mechanisms.J Mol Endocrinol. 1995 Jun;14(3):375-89. doi: 10.1677/jme.0.0140375. J Mol Endocrinol. 1995. PMID: 7669227
-
Abnormal transduction mechanisms in pituitary adenomas.Horm Res. 1997;47(4-6):227-34. doi: 10.1159/000185468. Horm Res. 1997. PMID: 9167956 Review.
Cited by
-
Dopamine (D2) receptor regulation of intracellular calcium and membrane capacitance changes in rat melanotrophs.J Physiol. 1996 Sep 15;495 ( Pt 3)(Pt 3):627-40. doi: 10.1113/jphysiol.1996.sp021621. J Physiol. 1996. PMID: 8887771 Free PMC article.
-
The Inhibitory Effect of Selected D2 Dopaminergic Receptor Agonists on VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New Therapy in Ophthalmic Diseases.Cells. 2022 Apr 2;11(7):1202. doi: 10.3390/cells11071202. Cells. 2022. PMID: 35406766 Free PMC article.
-
A study of tolerance to apomorphine.Br J Pharmacol. 1996 Mar;117(5):781-6. doi: 10.1111/j.1476-5381.1996.tb15260.x. Br J Pharmacol. 1996. PMID: 8851490 Free PMC article.
-
Molecular basis of pituitary oncogenesis.J Neurooncol. 1999;45(1):83-96. doi: 10.1023/a:1006390306336. J Neurooncol. 1999. PMID: 10728913 Review.
-
Prolactinomas in males: any differences?Pituitary. 2020 Feb;23(1):52-57. doi: 10.1007/s11102-019-01009-y. Pituitary. 2020. PMID: 31802331 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources